Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	292.16B
Revenue (ttm)	2.55B
Net Income (ttm)	-13.83B
Shares Out	6.57M
EPS (ttm)	-2,436.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,141,262
Average Volume	423,929
Open	41,600
Previous Close	40,800
Day's Range	40,800 - 45,750
52-Week Range	23,000 - 52,000
Beta	n/a
RSI	75.65
Earnings Date	Nov 14, 2025

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.